Penumbra (PEN)
(Delayed Data from NYSE)
$210.12 USD
+12.55 (6.35%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $209.94 -0.18 (-0.09%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth F Momentum C VGM
Penumbra (PEN) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Downside to Average Price Target |
---|---|---|---|
$187.46 | $215.00 | $150.00 | -5.12% |
Price Target
Based on short-term price targets offered by 13 analysts, the average price target for Penumbra comes to $187.46. The forecasts range from a low of $150.00 to a high of $215.00. The average price target represents a decline of 5.12% from the last closing price of $197.57.
Analyst Price Targets (13)
Broker Rating
Penumbra currently has an average brokerage recommendation (ABR) of 1.80 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 15 brokerage firms. The current ABR compares to an ABR of 1.53 a month ago based on 15 recommendations.
Of the 15 recommendations deriving the current ABR, eight are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 53.33% and 13.33% of all recommendations. A month ago, Strong Buy made up 66.67%, while Buy represented 13.33%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/PEN.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 8 | 8 | 10 | 10 | 10 |
Buy | 2 | 2 | 2 | 2 | 1 |
Hold | 5 | 5 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.80 | 1.80 | 1.53 | 1.53 | 1.50 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/31/2024 | William Blair | Margaret Kaczor | Strong Buy | Strong Buy |
7/31/2024 | Robert W. Baird & Co. | David Rescott | Strong Buy | Strong Buy |
7/31/2024 | Wells Fargo Securities | Lawrence H Biegelsen | Strong Buy | Hold |
7/31/2024 | Not Identified | Not Identified | Strong Buy | Hold |
7/31/2024 | Piper Sandler | Matthew O'Brien | Strong Buy | Strong Buy |
7/16/2024 | Truist Securities | Richard Newitter | Strong Buy | Strong Buy |
7/15/2024 | BTIG | Ryan Zimmerman | Strong Buy | Strong Buy |
5/9/2024 | Canaccord Genuity | William J Plovanic | Strong Buy | Strong Buy |
5/8/2024 | Needham & Company | Michael Matson | Hold | Hold |
5/8/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.80 |
ABR (Last week) | 1.80 |
# of Recs in ABR | 15 |
Average Target Price | $189.15 |
LT Growth Rate | 33.90% |
Industry | Medical - Instruments |
Industry Rank by ABR | 81 of 253 |
Current Quarter EPS Est: | 0.72 |